Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study.
Support Care Cancer
December 2024
Department of Medical Oncology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960‑1295, Japan.
Purpose: Cardiac dysfunction as a result of anthracycline treatment is a major concern regarding the management of patient life after therapy. The aim of the present study was to determine the clinical characteristics of cancer patients at high risk of developing cancer therapy-related cardiac dysfunction (CTRCD), in order to improve the risk management for the appropriate treatment.
Methods: This is a single-center, retrospective study of patients with breast cancer who underwent anthracycline treatment and had regular consultations with cardiologists.
Efficacy and safety of CalliSpheres drug-eluting bead bronchial arterial infusion chemoembolization vs. bland embolization in advanced lung cancer with hemoptysis: A multicenter retrospective study.
Biomol Biomed
November 2024
Department of Interventional Radiology, Affiliated Hospital of Jining Medical College, Jining, China.
Massive hemoptysis is a life-threatening complication in patients with advanced primary lung cancer, and effective, safe treatments are crucial. This study aimed to investigate the efficacy and safety of CalliSpheres drug-eluting bead bronchial arterial infusion chemoembolization (DEB-BACE) for managing this condition. A retrospective analysis included 144 patients with advanced primary lung cancer and massive hemoptysis treated at multiple hospitals from January 2019 to January 2023.
View Article and Find Full Text PDFImpact of MTHFD2 Expression in Bladder/Breast Cancer and Screening of Its Potential Inhibitor.
ACS Omega
November 2024
Molecular Virology Laboratories, Department of Biosciences, COMSATS University Islamabad, Islamabad 45550, Pakistan.
Genes of folate-mediated 1 carbon metabolism are found to be highly upregulated in tumor cells and promote cancer cell proliferation. The current study aimed to determine the expression of the MTHFD2 gene in bladder and breast cancers. Furthermore, the determination of potential ligand-based inhibitors against MTHFD2 was performed in comparison with those of chemotherapeutic drugs and natural plant-based compounds.
View Article and Find Full Text PDFEpirubicin/folic acid and meropenem loaded on graphene oxide-gelatin can be used as a novel candidate for anti-cancer and antibacterial drug development.
Int J Pharm
December 2024
Department of Microbial Biotechnology, College of Biotechnology, Amol University of Special Modern Technologies, Amol 46158-63111, Iran.
Resistance to meropenem and epirubicin poses a significant global threat, particularly in developing nations with constrained health resources. To overcome this problem, nanotechnology provides several promising solutions, including drug delivery systems that can improve the effectiveness of drugs. The objectives of this work is to characterize the anticancer mechanism of Graphene Oxide (GO) coated with Gelatin (Gel) and conjugated with the anticancer drug Epirubicin (EPi), along with functionalization with Folic Acid in SK-OV3 cancer cell lines for the first time.
View Article and Find Full Text PDFThe New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.
J Surg Oncol
October 2024
Department of General Surgery, School of Medicine, Koç University, Istanbul, Turkey.
Article Synopsis
- The FLOT 4-AIO trial demonstrated that a docetaxel-based treatment was more effective than an epirubicin-based regimen for patients with locally advanced resectable gastric cancer, but many patients didn't complete the full treatment plan of eight cycles.
- This study compared total neoadjuvant therapy (FLOT x8) with the standard approach (FLOT 4+4) to see which method improved treatment completion and tumor downstaging for patients with advanced gastric tumors prior to surgical removal.
- Results showed that the FLOT x8 group had a significantly higher completion rate of 89.1% compared to 67.6% in the FLOT 4+4
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!